Gothenburg medical-technology group listed on Nasdaq Stockholm (Vitrolife AB, org. 556354-3452; founded in 1994 as Scandinavian IVF Science AB) that supplies culture media, devices and genetic testing for in-vitro fertilisation. In May 2026 its Spanish subsidiary Vitrolife Medical Devices Spain, S.L.U. won the Unidade Local de Saúde Santa Maria’s tender for laboratory reagents for the human-reproduction unit at Lisbon’s Hospital de Santa Maria, worth €28,682 (TED award notice 341204-2026 of 19 May 2026).
Gothenburg medical-technology group listed on Nasdaq Stockholm (Vitrolife AB, org. 556354-3452; founded in 1994 as Scandinavian IVF Science AB) that supplies culture media, devices and genetic testing for in-vitro fertilisation. In May 2026 its Spanish subsidiary Vitrolife Medical Devices Spain, S.L.U. won the Unidade Local de Saúde Santa Maria’s tender for laboratory reagents for the human-reproduction unit at Lisbon’s Hospital de Santa Maria, worth €28,682 (TED award notice 341204-2026 of 19 May 2026).
Vitrolife sits inside the Portugal ↔ Scandinavia business corridor that NorthSouth HQ tracks every day. Its operations are a data point in the broader story of how capital, goods, people and ideas flow between Portugal and the Nordics — a corridor that is accelerating in 2026.
Fractio helps Nordic companies enter the Portuguese market — from market sizing to first sales, hiring, and legal setup.
Talk to Fractio →